News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ERYtech Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia
June 18, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LYON, France--(BUSINESS WIRE)--The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam (The Netherlands).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
October 30, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong